Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMN 351 Open-Label Extension in DMD
NCT07573631Phase 2Enrolling by invitation
- Sponsor
- BioMarin Pharmaceutical
- Start
- Apr 2026
- Primary completion
- Dec 2031
- Modality
- Gene Editing, Gene Silencing, Modified DNA Oligonucleotides
- Countries
- 5
01
Overview
A Phase 2 trial of BMN-351 in Duchenne muscular dystrophy (DMD), sponsored by BioMarin Pharmaceutical. Started Apr 2026; status: enrolling by invitation.
02
Drugs
BMN-351
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT07573631.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07573631.